Sepsis Diagnostics Market Growth Opportunities and Forecast by 2028

The sepsis diagnostics market is projected to reach US$ 1,226.52 million by 2028 from US$ 661.83 million in 2021; it is expected to grow at a CAGR of 9.2% from 2021 to 2028.

Factors such as the surging incidence of sepsis due to increasing nosocomial infections and rising demand for rapid diagnostic tests leading to increasing product launches drive the sepsis diagnostics market growth.

Sepsis is a serious and life-threatening clinical condition that generally results from primary bacterial infection or, less frequently, from a fungal and/or viral infection. Three stages of sepsis are sepsis, severe sepsis, and the final stage of septic shock. Sepsis diagnostics is the study of diagnosis of this condition.

North America is likely to dominate the sepsis diagnostics market during the forecast period. The US held the largest share of the North American market in 2021 and is expected to continue this trend during the forecast period. Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Increasing prevalence of sepsis and surging investments in the research and development of sepsis diagnosis are projected to accelerate the sepsis diagnostics market growth in the region. Moreover, the presence of large healthcare market players results in the growing sepsis diagnostics product launches.

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Sepsis Diagnostics Market: Strategic Insights

The sepsis diagnostics market is segmented on the basis of product, technology, method, test type, pathogen, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The sepsis diagnostics report offers insights and in-depth analysis of the market, emphasizing parameters such as market trends, technological advancements, market dynamics, and the competitive analysis of the globally leading market players.

Market Insights

High Incidence of Sepsis due to Increasing Nosocomial Infections

Sepsis mainly occurs in immunocompromised people, such as those taking chemotherapy, having a splenectomy, and suffering from AIDS and chronic illnesses like diabetes. Hospital-acquired infections, also known as nosocomial infections, are the primary cause of morbidity and mortality among hospitalized patients. According to the "2020 National and State Healthcare-Associated Infections Progress Report" published by the Centers for Disease Control and Prevention (CDC) in 2021, about 24%, 35%, and 15% increase was recorded in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia, respectively, in the US between 2019 and 2020. Thus, the rising bloodstream infections will increase the adoption of sepsis diagnostic products.

In September 2020, World Health Organization (WHO) estimated that each year almost 50% cases of sepsis are seen among children, and 2.9 million deaths occurred in children. Most deaths can be prevented through early diagnosis and appropriate clinical management. Thus, the high incidence rate of sepsis boosts the demand for sepsis diagnostic products, thereby supporting the sepsis diagnostics market growth.

Product Insights

Based on product, the global sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. In 2021, the blood culture media segment held the largest share of the market. According to the Journal of the Academy of Clinical Microbiologists report, blood culture media remains one of the most critical investigations in the sepsis management as it allows identification of the responsible organism for sepsis, appropriate choice of empirical and specific antibiotics, and points towards further investigations for identifying the focus on infection. A blood culture media is recommended for all septic patients. However, the software segment is anticipated to register the highest CAGR in the market during the forecast period.

Technology Insights

Based on technology, the global sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. In 2021, the microbiology segment held the largest share of the market. Rapid and specific pathogen identification is important for sepsis treatment, and microbiological techniques act as the gold standard for sepsis pathogen identification that can be done through blood culture followed by sub culturing and pathogen identification through biochemical or microscopic means. However, the molecular diagnostics segment is expected to register the highest CAGR in the market during forecast period. 

Method Insights

Based on method, the global sepsis diagnostics market is bifurcated into automated diagnostics and conventional diagnostics. In 2021, the conventional diagnostics segment held a larger share of the market. However, the automated diagnostics segment is expected to register a higher CAGR in the market during forecast period. Conventional diagnostics procedure for sepsis takes a few days. Thus, conventional diagnostics method is slowly adopted than automated diagnostics. Also, companies focus on developing automated diagnostics based on advanced technologies, such as molecular diagnostics for detecting sepsis.

Test Type Insights

Based on test type, the global sepsis diagnostics market is segmented into point-of-care tests and laboratory tests. In 2021, the laboratory tests segment held a larger share of the market. However, the point-of-care tests segment is expected to register a higher CAGR in the market during forecast period. POC platforms can lead to timely intervention with appropriate therapeutics as it simplifies the needs of the diagnostics process by offering accessible and affordable clinical information to detect sepsis at a much earlier stage.

Pathogen Insights

Based on pathogen, the global sepsis diagnostics market is segmented into bacteria sepsis, fungal sepsis, and others. In 2021, the bacteria sepsis segment held the largest market share. Moreover, the same segment is expected to register the highest CAGR in the market during forecast period.

End User Insights

Based on end user, the global sepsis diagnostics market is segmented into hospitals, pathology and reference laboratories, and others. In 2021, the hospitals segment held the largest share of the market. However, the pathology and reference laboratories segment is expected to register the highest CAGR in the market during forecast period.

Product launches and collaborations are highly adopted strategies by the global sepsis diagnostics market players to expand their global footprints and product portfolios. The players also focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name globally. They aim to flourish their market shares with the development of innovative products. A few of the recent key market developments are listed below:

• In November 2021, T2 Biosystems, Inc. executed territory exclusive distribution agreement in Taiwan. Under the terms of the agreement, T2 Biosystems will sell T2Dx Instruments, along with T2Bacteria, T2Candida, and T2Resistance Panels through its distributor. T2 Biosystems and its new distribution partner are collaborated with the health authorities in Taiwan to gain regulatory approval and offer the highest quality sepsis care to patients.
• In May 2019, Danaher subsidiary Beckman Coulter launched Access PCT assay. The state-of-the-art sensitivity and low-end precision of Access PCT assay combined with short incubation time help physicians in the risk assessment of critically ill patients in danger of progression to severe sepsis or septic shock, with test results available in under 20 minutes. The new Access PCT assay received CE mark certification and available for use on the Access Family of Immunoassay Systems, including the Access 2, UniCel DxI 600, and UniCel DxI 800.

The regional trends and factors influencing the Sepsis Diagnostics Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Sepsis Diagnostics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Sepsis Diagnostics Market Report Scope

Sepsis Diagnostics Market Players Density: Understanding Its Impact on Business Dynamics

The Sepsis Diagnostics Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Sepsis Diagnostics – Market Segmentation

The global sepsis diagnostics market is segmented on the basis of product, technology, method, test type, pathogen, and end user. In terms of product, the global sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. Based on technology, the sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. In terms of method, the market is segmented into automated diagnostics and conventional diagnostics. Based on test type, the global sepsis diagnostics market is segmented into point-of-care tests and laboratory tests. In terms of pathogen, the market is segmented into bacteria sepsis, fungal sepsis, and others. In terms of end user, the sepsis diagnostics market is segmented into hospitals, pathology and reference laboratories, and others.

Company profile

• Abbott
• F. HOFFMANN-LA ROCHE LTD.      
• Immunexpress Inc.           
• BD    
• Danaher      
• Luminex Corporation         
• Thermo Fisher Scientific Inc.         
• bioMerieux SA.       
• T2 Biosystems, Inc.           
• Axis-Shield Diagnostics Ltd.